Is Compounded Semaglutide Legal in 2026? What the FDA Rules Say

Compounded semaglutide is not banned by name, but the window that made mass compounding legal has closed. The FDA determined on February 21, 2025 that the shortage of semaglutide injection products was resolved, which ended the special pathway that had allowed pharmacies and outsourcing facilities to compound copies of Ozempic and Wegovy since 2022 ^[1]. The enforcement-discretion wind-down periods ran until April 22, 2025 for state-licensed pharmacies and physicians compounding under section 503A, and until May 22, 2025 for outsourcing facilities under section 503B ^[1][2]. As stated by the FDA on April 1, 2026, semaglutide does not appear on the 503B bulks list or on the FDA drug shortage list, and neither does tirzepatide ^[1][5].

That does not mean every compounded semaglutide product is automatically illegal. Compounding remains lawful in narrow circumstances, mainly when a prescriber determines and documents that a compounded product is medically necessary for one identified patient because no available FDA-approved drug can meet that patient’s needs ^[2][3]. What ended is large-scale compounding of products the FDA considers “essentially a copy” of a commercially available drug. Compounded drugs are not FDA approved, meaning the FDA does not review their safety, effectiveness, or quality before they are marketed ^[2][5]. Absent an exemption, compounded copies may be deemed misbranded, which could result in enforcement action including a warning letter, seizure, or injunction ^[5].

Did the FDA ban compounded semaglutide outright?

No. The FDA never issued a rule that bans compounded semaglutide by name. What changed is that the drug left the FDA shortage list, which closed the exemption compounders had been relying on ^[1][2].

Under the FD&C Act, a compounded drug that is essentially a copy of a commercially available drug cannot qualify for the compounding exemptions unless an exception applies, such as the approved drug being on the shortage list at the time of compounding, distribution, and dispensing ^[2][5]. Once the FDA determined the semaglutide shortage was resolved on February 21, 2025, that exception stopped being available ^[1]. The FDA’s declaratory order does not restrict compounders from compounding semaglutide injection products that are not essentially a copy of an FDA-approved drug and that are compounded to meet individual patient needs, such as a different dose or different inactive ingredients ^[2].

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

A 503A pharmacy is a state-licensed pharmacy or physician that compounds a drug for an identified individual patient based on receipt of a prescription ^[1][5]. A 503B outsourcing facility compounds drugs at a larger scale, generally for office use at health facilities ^[2].

The two pathways have different rules for bulk ingredients. A 503A compounder may not compound, regularly or in inordinate amounts, drug products that are essentially copies of a commercially available drug ^[1][5]. A 503B outsourcing facility is restricted from compounding drugs using bulk drug substances unless the substance appears on the 503B bulks list, which identifies bulk substances for which there is a clinical need, or the compounded drug is on the FDA’s drug shortage list at the time of compounding, distribution, and dispensing ^[1][5][6].

	503A pharmacy or physician	503B outsourcing facility
Who it serves	An identified individual patient, based on a prescription [1][5]	Larger-scale compounding for office use at health facilities [2]
Copy restriction	May not compound essentially copies regularly or in inordinate amounts [1][5]	Restricted from using bulk drug substances unless on the bulks list or shortage list [1][5][6]
Wind-down end for semaglutide copies	April 22, 2025 [1][2]	May 22, 2025 [1][2]

How did the shortage pathway open, and how did it close?

Semaglutide injection products went into shortage in 2022 because of increased demand ^[1]. The FDA added Wegovy to its drug shortage list in March 2022 and Ozempic in August 2022 ^[2]. While the drugs were listed in shortage, compounders could rely on the shortage exception to make copies.

On February 21, 2025, the FDA determined the shortage of semaglutide injection products was resolved ^[1]. The FDA confirmed with the drug’s manufacturer that stated product availability and manufacturing capacity could meet present and projected national demand ^[1]. In reaching that decision, the FDA considered the manufacturer’s production capability, existing inventory, and wholesaler inventory, along with input from telehealth companies, pharmacy compounders, associations representing compounders and outsourcing facilities, and individuals ^[2].

To avoid unnecessary disruption to patient treatment, the FDA gave compounders wind-down periods during which it did not intend to take action for violations arising from the drugs’ shortage-list status: 60 calendar days for 503A pharmacies and physicians, until April 22, 2025, and 90 calendar days for 503B outsourcing facilities, until May 22, 2025 ^[1][2]. The FDA noted that patients and prescribers may still see intermittent and limited localized supply disruptions as products move through the supply chain ^[1].

The tirzepatide timeline ran earlier. The FDA declared the tirzepatide injection shortage resolved on December 19, 2024 ^[1]. As of February 21, 2025, dulaglutide injection and liraglutide injection were still listed in shortage ^[1]. Compounded versions were big business while the shortage lasted: in 2024, they accounted for an estimated 30% of the overall GLP-1 weight-loss market ^[4].

What happened in court?

The Outsourcing Facilities Association (OFA), a trade group representing compounding pharmacies, sued the FDA over the shortage determinations. OFA claimed the agency was “abruptly depriving patients of much needed treatment and artificially raising drug prices,” and argued that the FDA ignored evidence that shortages continued and gave compounders no reasonable notice or chance to comment ^[4].

Compounders lost at both levels. On March 5, 2025, the district court denied OFA’s preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.), concerning tirzepatide ^[1]. On April 24, 2025, the district court denied the preliminary injunction motion in the semaglutide case, Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) ^[1][3].

An appeals court, the U.S. Court of Appeals for the Fifth Circuit, then affirmed in an August 27 ruling that the FDA’s removal of semaglutide and tirzepatide from the shortage list was lawful, finding the agency “followed the statutory framework, applying the statutory definition of shortage to the evidence before it” ^[4]. The court also endorsed the FDA’s reliance on actual supply data from manufacturers, finding that pharmacy screenshots, patient reports, articles, blog posts, and form letters submitted by compounders were less probative than “more specific, reliable, comprehensive, and current” data from the manufacturer ^[4].

What does “essentially a copy” mean now?

On April 1, 2026, the FDA issued a statement clarifying its policies for compounders, and for the first time it expressly stated what it considers compounding, regularly or in inordinate amounts, a drug product that is essentially a copy of a commercially available drug product ^[1][5].

Under the clarified policy, the FDA intends to consider a compounded drug product essentially a copy when both of the following are true ^[1][5]:

• The compounded product has the same active pharmaceutical ingredient or ingredients as the commercially available product, in the same, similar, or easily substitutable strength.
• The commercially available product can be used by the same route of administration prescribed for the compounded product, regardless of how the commercial product is labeled.

The same test applies when a compounded product contains the same APIs as two or more commercially available products ^[1]. The exception is when a prescriber determines and documents that the compounded product contains a change producing a significant difference from the commercially available product for an identified individual patient ^[1][5].

One important limit: this clarification is a statement of FDA policy, and it does not have the force and effect of law ^[5].

Does adding vitamin B12 make compounded semaglutide legal?

No. The FDA specifically addressed this workaround in its April 1, 2026 statement. A compounded product that combines semaglutide API with another API, such as vitamin B12 (cyanocobalamin), will be considered essentially a copy of a commercially available drug product when the products are used by the same route of administration, such as injection, and the amounts of semaglutide and vitamin B12 in the compounded product are within 10% of the strengths of the respective commercially available drug products ^[1][5].

Simply adding another substance such as vitamin B12 is pharmacy- and population-driven and does not meet the patient-specific exception ^[3]. And drug cost is an insufficient basis for a medical-necessity claim, per FDA guidance ^[3].

Can my doctor still get a compounded version made just for me?

A narrow patient-specific route remains open, but it is limited. The FDA’s order does not restrict compounding of semaglutide injection products that are not essentially a copy of an FDA-approved drug and that are compounded to meet individual patient needs, such as a different dose or different inactive ingredients ^[2].

The exception must be patient-specific: the patient must meet all the criteria, and it does not apply broadly to a general population ^[3]. An authorized provider must determine that a patient needs a personalized medication for a specific, medically necessary reason, and must document that determination on the prescription submitted to the compounding pharmacy and in the patient’s medical record ^[3]. The exception can only be used when a patient’s medical needs cannot be met by an available FDA-approved drug, for example an allergy to an ingredient in an approved formulation, or an inability to swallow pills when the drug is only available in pill form ^[3].

The determination and the risk shift to the prescriber ^[3]. Whether a particular situation qualifies is a question for a licensed clinician, and readers with legal questions should speak with an attorney. One open issue: the FDA has not specified the type or amount of documentation a prescriber must create and maintain for a significant-difference determination ^[5].

What is the four-prescriptions-a-month threshold?

In its April 1, 2026 statement, the FDA said that, at this time, it does not intend to take action against a 503A compounder for compounding an essentially-copy product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month ^[1][5].

This is not a legal safe harbor. It is stated enforcement intent within a policy clarification that, as noted above, does not have the force and effect of law ^[5]. The FDA could change this position, and the threshold does not make an otherwise non-compliant product lawful.

What is the 503B bulks list proposal?

On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, after evaluating nominations and finding no clinical need for outsourcing facilities to compound these drugs from bulk substances ^[6]. A determination of clinical need is based on patient safety and medical necessity under the law ^[6].

FDA Commissioner Marty Makary said: “When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need” ^[6].

The Federal Register notice was published on May 1, 2026 (91 FR 23431, Docket No. FDA-2018-N-3240, 14 pages) ^[7]. The initial comment deadline was June 29 or June 30, 2026, depending on the source ^[6][7]. A notice issued on June 26, 2026 extended the comment deadline to July 30, 2026 in response to an extension request ^[8]. The FDA will consider submitted comments before making a final determination ^[6].

What does the proposal change versus what is already true?

Less than it might sound like. 503B compounding from bulk semaglutide is already not permitted, because the substance appears on neither the 503B bulks list nor the FDA drug shortage list ^[1][5]. The proposal would make that exclusion explicit on the bulks list, but it is not a final determination; the FDA states it will decide after reviewing comments ^[6]. No final determination has been published in the sourced material.

What should someone using a compounded product do now?

Providers who relied on compounded semaglutide needed transition plans so patients could continue care without disruption ^[2]. Patients switching to FDA-approved products should anticipate insurance barriers such as prior authorization ^[2].

It is also worth knowing that the FDA’s enforcement-discretion deadlines only covered violations tied to the shortage-list status. The FDA has stated it may still act on other violations, such as findings that a product is of substandard quality or otherwise unsafe ^[1]. Questions about a specific prescription or medical situation belong with a licensed clinician, and legal questions belong with an attorney.

Sources

1. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
2. Alston & Bird. FDA Resolves Semaglutide Shortage: Next Steps for Community Pharmacies, Telehealth Companies, and Other Providers. March 12, 2025.
3. American Med Spa Association. Semaglutide Compounding to End.
4. National Consumers League. National Consumers League Welcomes the Appeals Court Ruling Backing FDA’s Decision to Remove GLP-1 Drugs from the Shortage List.
5. Foley & Lardner. FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products. April 14, 2026.
6. US Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List.
7. Federal Register. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act. May 1, 2026.
8. US Food and Drug Administration. Federal Register notice on prednisolone tablet, 5 mg, citizen petition determination. June 26, 2026.
9. Medical Daily. Public Comment Closes on the FDA Plan to Permanently Bar Bulk Compounding of Semaglutide and Tirzepatide.
10. US Food and Drug Administration. FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients.
11. AJMC. FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads. February 9, 2026.
12. Mississippi Board of Nursing, Mississippi Board of Pharmacy, and Mississippi State Board of Medical Licensure. Joint Statement Concerning the Prescribing of Non-FDA Approved (Research-Grade) Peptides. August 19, 2026.
13. US Food and Drug Administration. Warning Letter: Gram Peptides - 721806. March 31, 2026.
14. Dykema. Congress Introduces SAFE Drugs Act of 2025, Expanding FDA Oversight of Compounded GLP-1 Drugs and Telehealth Providers.
15. Novo Nordisk. Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded “semaglutide”.
16. Reuters. Lilly, Novo defeat antitrust lawsuit over GLP-1 drug market. August 6, 2026.
17. US Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s.
18. Reuters. US FDA sends 25 letters to telehealth companies over claims on compounded weight-loss drugs. June 16, 2026.
19. AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026.
20. Buchanan Ingersoll & Rooney PC. FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead.
21. Centers for Medicare & Medicaid Services. Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries. May 6, 2026.
22. Congress.gov. H.R.6509 - SAFE Drugs Act of 2025, 119th Congress (2025-2026).